Biosimilars may need more time to devleop in the market.
Biologic medicines could lower spending by $153 billion by 2023.
New changes are making it more difficult for generics and biosimilars to compete on formularies.
Blockbuster drug could be key to Humira’s successor.
Biosimilar guidance provides “clarity” for drug developers.
Indicated for breast cancer, and gastric or gastroesophageal junction adenocarcinoma.
Only new biosimilars and interchangeables will recieve four-letter suffixes.
The report by Magellan Rx Management indicates PMPM, site of service, and Medicaid prices continue to increase.
Specialty pharmaceuticals make up a significant part of the current drug market, and their impact is only going to grow over the next few years.
Better care at lower costs is the ultimate goal across healthcare today. Here’s how pharmacists can help.